U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07201558) titled 'Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants' on Sept. 30.
Brief Summary: This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.
Study Start Date: Nov. 28
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Intervention:
BIOLOGICAL: Surovatamig
Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK...